Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
49 results about "Genetic transduction" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Virus mediated transfer of genetic material between cells; also refers to the transfer of bacterial DNA by phages.
Methods of treating HIV infected subjects
InactiveUS6905680B2Expanding population of cellIncrease the number ofVirusesPeptide/protein ingredientsAccessory moleculeExogenous growth
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR) / CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Owner:GENETICS INST INC +2
Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Methods of Tranducing genes into T cells
InactiveUS20060104950A1Good effectImprove efficiencySsRNA viruses negative-senseBiocideGene deliveryT cell
The present invention provides methods of transducing a gene into activated T cells comprising the step of contacting a paramyxovirus vector with activated T cells. This invention also provides a method of preparing T cells transduced with a foreign gene comprising the step of contacting a paramyxovirus vector with activated T cells. This invention also provides T cells transduced with a foreign gene prepared by this method. The present invention enables efficient gene transduction specific to activated T cells, and is expected to be applied to immunological modification strategies using T cell-directed gene delivery.
Owner:DNAVEC RES
Methods for treating HIV infected subjects
InactiveUS20060099177A1Increase the number ofInhibit productionBiocideAntibody mimetics/scaffoldsAccessory moleculeExogenous growth
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR) / CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Owner:GENETICS INST INC +2
Gene transduction method with nano granule as carrier based on ultrasonic intervention guiding
InactiveCN1687427ALow priceEasy to operateImmobilised enzymesOther foreign material introduction processesParticulatesCell wall
A gene transduction method ultrasonic-based, which using the nano particulate as the carrier. It consists of animal transgenic gene method and plant transgenic gene method. The outer gene joins with the particulate with the effect of static form together to form the gene carrier, which can protect the DNA being broken by ultrasonic. The ultrasonic synchronously give effect to particulate gene carrier, cells, organize and apparatus, the carrier can run efficiently through the short period alleyway of cell wall, cell film, core film cell, enables the outer gene constructs with the gene group in cell. This method has a high efficiency, and is provided with convenient manipulation, high efficiency, no request of differential function e.g. other merits. It can be applied widely to these range, animal and plant transgenic technology and genic cure of human being.
Owner:HUNAN UNIV
Attenuated, brightened and replication-controllable HSV recombinant virus, preparation method and applications thereof
InactiveCN107630009AEasy genetic manipulationEasy to insertViruses/bacteriophagesFermentationCell specificNervous system
The invention discloses attenuated, brightened and replication-controllable HSV recombinant virus, a preparation method and applications thereof. According to the present invention, thymidine kinase (TK) gene essential for replicating viruses in neurons and being a main virulence factor is knocked out by using a homologous recombination method, and subsequently a red or green fluorescent gene enhancement expression cassette is recombined into the genome of the virus to construct a series of novel recombinants viruses, wherein the toxicity is markedly low, the states of infected mice are good,the fluorescence signal is strong, and the expression of the recombinant viruses is limited at the injection site after the recombinant viruses are used in in-vivo animal center labeling; by combiningwith Cre-dependent AAV helper viruses capable of expressing TK in a compensated manner, the cell-specific transmonosynaptic loop tracing is achieved; and the recombinant HSV has wide application value in nervous system targeted gene transduction, neural network transsynaptic tracing, tumor disintegration, viral replication and pathogenesis mechanism, antiviral drug screening and other fields.
Owner:WUHAN INST OF PHYSICS & MATHEMATICS CHINESE ACADEMY OF SCI
Solution of chitosan, preparation method thereof and using method thereof
ActiveCN101698712AAchieve dissolutionSolve the technical problems of insolubleGenetic engineeringFermentationPhysical Chemistry ConceptsGene
The invention relates to the fields of macromolecular substances, physical chemistry, molecular biology and virology, in particular to solution of chitosan, preparation method thereof and a method for using the same to improve the efficiency of gene transduction mediated by an adenoviral vector.
Owner:INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI
Chimeric vectors and their use for heterologous genes transfer
Owner:CONSORZIO INTERUNIVRIO PER LE BIOTECH
Myoblast therapy for cosmetic treatment
InactiveUS7341719B1Good lookingFunction increaseBiocideGenetic material ingredientsDiseaseMyogenic cell
Compositions and methods of treating mammalian diseases using myoblasts, and / or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and / or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and / or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted / released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells. Endogenous biochemical(s) are used to control cell fusion of myoblasts among themselves or with other cell types. An automated cell processor within a cell bank which enables the manufacture, at a single run, of unprecedented large quantities (greater than 100 billion) of normal or genotypically or phenotypically altered myogenic cells is also disclosed.
Owner:LAW PETER K
Method Of Differentiation From Stem Cells To Hepatocytes
InactiveUS20120231490A1Induced differentiationEffectively lead to differentiationMicrobiological testing/measurementGenetically modified cellsHepatocyteGenetic transduction
Disclosed are: a gene transduction method for use in the induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes effectively; stem cells into each of which a gene useful for the induction of the differentiation into hepatocytes is introduced; and hepatocytes produced from stem cells each having the gene introduced therein. A specific gene can be introduced into stem cells such as ES cells or iPS cells using an adenovirus vector. The effective induction of the differentiation into hepatocytes can be achieved by introducing the gene. Specifically, the effective induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes can be achieved by introducing at least one gene selected from HEX gene, HNF4A gene, HNF6 gene and SOX17 gene into the stem cells.
Owner:HEALTH SCI TECH TRANSFER CENT JAPAN HEALTH SCI FOUND
Low-toxic herpes simplex virus system and construction method and application thereof
PendingCN110117577AEasy genetic manipulationEasy to insertVirus peptidesFermentationDiseaseFine structure
The invention discloses a recombinant low-toxic herpes simplex virus system derived from a herpes simplex virustype I H129 clinical toxic strain and a construction method and application thereof. A recombinant virus constructed by a target vector is a remarkably attenuated H129 recombinant virus, the abundance of exogenous gene expression is very high, the characteristics of low toxicity and long-term high expression are shown in in vitro test or animal in vivo test, center infected animals cannot cause diseases, many neurons in brain regions are highlighted, and neuron cell bodies, axonal / dendritic fiber, dendritic spines and other fine structures are marked clearly. The low-toxic herpes simplex virus is suitable for serving as a target gene long-term and high-expression gene transductionvector and achieving long-term structure tracing of a neural circuit, and due to low toxicity, the low-toxic herpes simplex virus is also suitable for functional neural circuit analysis; in addition,the low-toxic HSV has wide application value in the aspects of nervous system targeted gene therapy, virus replication and pathogenesis analysis, animal infection model establishment, antiviral drugscreening, oncolytic therapy and the like.
Owner:WUHAN INST OF PHYSICS & MATHEMATICS CHINESE ACADEMY OF SCI
Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
InactiveUS20140051171A1Reduce riskLimited regeneration capacityNervous disorderGenetically modified cellsSerum free mediaReprogramming
This application relates to a method for converting somatic cells to Neural Stem Cells (NSCs). Moreover this application relates to a method for converting human fibroblasts, keratinocytes or adipocytes to neural stem cells based on linked steps of genes transduction and chemically defined medium induction.
Owner:F HOFFMANN LA ROCHE INC
Nucleocapsid assembling necessary element and application thereof
The invention relates to the assembling field of virus nucleocapsid, particularly to a baculovirus nucleocapsid assembling necessary element and an application thereof in nucleocapsid assembling, establishment of a carrier comprising a target nucleotide sequence, and the like. The nucleocapsid assembling necessary element disclosed by the invention comprises a 45-65 map unit positioned in a viral genome of a hepatitis A baculovirus, preferably, a DNA sequence in the position of a 47-61 map unit. An NAE sequence plays an essential role in the nucleocapsid assembling process. The baculovirus has wide application prospect in the gene transduction field, so that the NAE sequence found in the invention can improve a baculovirus gene-transduced carrier, so that the establishment process is simpler and more convenient, the target DNA is higher in capacity, and higher biosecurity is achieved; and therefore, the nucleocapsid assembling necessary element is applicable to a required gene transduction operation, and requirements of clinical application, such as gene therapy and the like, can be better satisfied.
Owner:SUN YAT SEN UNIV
In vivo gene transduction device
InactiveCN101168744AAvoid damageThe excitation electric field is reducedInfusion syringesOther foreign material introduction processesHigh-voltage direct currentAlternating current
The invention discloses a vivo gene transduction method and the device thereof. The device consists of a bielectrode needle provide with double syringe tubes, a high-voltage alternating current sine wave signal generator, a high-voltage direct current signal generator, and a microcomputer controlled chopping module. The invention adopts the bielectrode needle of the double syringe tubes to inject DNA into muscular tissues, and simultaneously applies excitation electric fields with specific parameters to the muscular tissues where the DNA is positioned, thereby realizing that the excitation electric field intensity of the original normal electrode device applied to the muscular tissue layer is reduced from 200-700 V / cm to 20-50 V / cm under the condition of maintaining equally transduction efficiency with the normal electrode, and greatly reducing the injury to the muscular tissues. The invention has the advantages of small size, light weight, adjustable parameters, friendly clinical application interface, etc., thereby realizing safe and efficient vivo gene transduction, and providing a new method and a new tool for further carrying on clinical gene therapy tests and researches.
Owner:XI AN JIAOTONG UNIV
Interferon alpha and antisense K-ras RNA combination gene therapy
InactiveUS20050260167A1Increased cell deathEasy to solveBiocideSugar derivativesAbnormal tissue growthWhole body
An antiproliferative effect of IFN-α gene transduction in pancreatic cancer cells. The invention relates to expression of IFN-α to effectively induce growth suppression and cell death in pancreatic cancer cells, an effect which appeared to be more prominent when compared with other types of cancers and normal cells. Another aspect of the invention relates to targeting the characteristic genetic aberration, K-ras point mutation, in pancreatic cancer, and that the expression of antisense K-ras RNA significantly suppresses the growth of pancreatic cancer cells. When these two gene therapy strategies are combined, the expression of antisense K-ras RNA significantly enhanced IFN-α-induced cell death (1.3-3.5 fold), and suppressed subcutaneous growth of pancreatic cancer cells in mice. The invention also relates to a method of suppressing pancreatic cancer cells using double strand RNA formed by antisense and endogeneous K-ras RNA in combination with the anti-tumor activity of IFN-α. The invention relates to the combination of IFN-α and antisense K-ras RNA as an effective gene therapy strategy against pancreatic cancer. The invention also relates to a method of treating pancreatic cancer cells disseminated throughout the body by administering the inventive combination to localized pancreatic cancer cell tumor. The invention also relates to inducing indirect immunological antitumor activity to provide systemic immunity against pancreatic cancer cells.
Owner:HEALTH SCI TECH TRANSFER CENT JAPAN HEALTH SCI FOUND
Biotin-avidin-lentiviral expression vector and CAR-T (chemric antigen receptor T) cell preparation method and visualization scheme
InactiveCN106282237AEasy to manufactureShorten the timeRadioactive preparation carriersFermentationAntigen receptorsImage detection
The invention provides a biotin-avidin-lentiviral expression vector and a CAR-T (chemric antigen receptor T) cell preparation method, and aims at solving the defects of single targeting ability, complex preparation, time-consuming and labor-consuming properties and poor economical efficiency of traditional CAR-T. The method comprises the following steps of constructing an avidin-CAR lentivirus package carrier; performing virus packaging; and performing T cell separation, activation, co-stimulation structural domain gene transduction and amplification, thereby preparing CAR-T cells. On the basis of a general CAR-T treatment system, a molecular imaging detection means is introduced, a cell-based visualization treatment scheme is provided, and a CAR-T cell treatment process can be dynamically monitored in vivo in real time, so that a situation that the current CAR-T cell treatment process is lack of effective monitoring is solved. The biotin-avidin-lentiviral expression vector has the advantages of simplicity in preparation, diversity in selection, extensive targets and visualization on treatment process, and suitability for treatment of tumor patients.
Owner:PEKING UNIV
HM1.24-utilizing cancer vaccines
A cancer vaccine containing as an active ingredient an antigen-specific dendritic cell pulsed by an HM1.24 protein, HM1.24 peptide or transduced with an HM1.24-encoding gene, or HM1.24 protein-encoding DNA or RNA.
Owner:CHUGAI PHARMA CO LTD +1
Novel vesicle-like oncolytic virus and application thereof in preparation of antitumor drugs
PendingCN112941039AAchieve retargetingIncrease the window periodPeptide/protein ingredientsAntibody mimetics/scaffoldsViral antibodyAntiendomysial antibodies
The invention belongs to the field of tumor treatment and relates to application of a novel vesicle-like oncolytic virus in preparation of antitumor drugs. The virus Ad5sPVRCD137L infects cells capable of expressing specific membrane protein VSV-G, then a centrifugal extrusion / shearing method is utilized to enable the cells to pass through membrane holes so as to form vesicles, the oncolytic virus wrapped by the vesicles is manufactured, and the membrane protein VSV-G on the surfaces of the cells is reserved on the outer surfaces of the vesicles in the preparation process. The prepared novel vesicle-like oncolytic virus can achieve heavy targeting through the membrane protein VSV-G, and therefore, the gene transduction efficiency of the virus is improved, the neutralizing effect of an antiviral antibody can be avoided, and the yield of the virus can be improved; and a soluble fusion protein sPVRCD137L expressed by the virus can achieve the dual functions of blocking an immune detection point and activating immune costimulation. The novel vesicle-like oncolytic virus can significantly activate anti-tumor immunity and finally significantly prolong survival of mice.
Owner:NANJING UNIV
Method for transferring bone marrow filling dry cell by TPO/FL
InactiveCN1818071AReduce needLow costVector-based foreign material introductionForeign genetic material cellsMesenchymal stem cellPcr ctpp
The invention provided a method of transducing the marrow stem cell by the TPO / FL gene. (1) The mRNA of the TPO and the FL is separated from the human fetus liver, then to synthesis the two cDNA by the RT-PCR and clone it to the pBluescript carrier to construct the FL-IRES-TPO fragment, then to transform the fragment to the reverse transcription virus carrier to construct the pfl30 expression carrier. (2) transducing the marrow stem cell by the pfl30 expression carrier to construct the marrow stem cell with the high expression of the exogenous TPO and the FL. The stem cell is in the hemopoietic stem / ancestor cell in vitro culture system, so it can save the cost and improve the refresh, amplified and differential ability of the hemopoietic stem cell.
Owner:ZHEJIANG UNIV +1
Somatotransgenic bioimaging
InactiveCN101680032AMicrobiological testing/measurementVector-based foreign material introductionModel diseaseBiology
Owner:UCL BUSINESS PLC
Novel oncolytic adenovirus EM/VSV-G Ad5-P and application thereof in preparation of antitumor drugs
PendingCN113832114AHigh expressionEnsure the effect of anti-tumor therapyPeptidesUnknown materialsOncolytic adenovirusTumor therapy
The invention relates to the field of tumor treatment, in particular to application of oncolytic adenovirus EM / VSV-G Ad5-P in preparation of antitumor drugs. The invention discloses an antitumor effect of the oncolytic adenovirus EM / VSV-G Ad5-P in vivo and in vitro. The exosome-like coated oncolytic adenovirus EM / VSV-G Ad5-P, hereinafter referred to as a novel virus, is prepared by using cells expressing VSV-G and utilizing an exosome-like technology. The novel virus realizes heavy targeting through VSV-G, infects a CAR low-expression cell line, increases the gene transduction efficiency of the virus, can resist the neutralization effect of a virus antibody, and also can increase the virus yield. In-vitro research finds that the infection efficiency, the oncolytic ability and the PD-1 expression quantity of the novel virus are remarkably improved in a CAR low-expression cell line. In-vivo experiments show that the novel virus can resist neutralization of an Ad5 antibody, prolong a virus treatment window and continuously express PD-1, so that the novel virus can remarkably activate anti-tumor immunity and finally remarkably prolong survival of mice.
Owner:NANJING UNIV
Method for inducing immune tolerance through targetted gene expression
A method of inducing immune tolerance against a protein of interest comprising the steps of (a) transducing hematopoietic stem cells with a gene for the protein of interest wherein the gene is operably connected to a platelet specific promoter, and (b) transplanting the transfected cells of step (a) into to a subject, wherein the protein is expressed, and wherein the subject develops immune tolerance against the protein.
Owner:VERSITI BLOOD RES INST FOUND INC
Lipid ultrasound microbubble mediated adeno-associated virus gene transfection preparation and preparation technology thereof
InactiveCN102813942AFacilitates transmembrane transfectionImprove permeabilityGenetic material ingredientsPharmaceutical non-active ingredientsCell membraneAdeno-associated virus
The invention relates to an adeno-associated virus based and lipid ultrasound microbubble mediated novel preparation capable of obviously improving gene transfection efficiency on cells with compact structure. A structure of the novel preparation is shown as a figure 1, and consists of three parts: an adeno-associated virus, perfluoropropane, and a lipid bilayer. According to the invention, the advantage of efficient gene transfection of the adeno-associated virus vector is utilized; under the effect of ultrasound, the ''cavitation effect'' generated by the ultrasound microbubbles acts on cell membranes of the cells with compact structure to generate ''overflow pores'' and increase permeability of the cell membranes, so that adeno-associated viruses released after destruction of the microbubbles can enter blood vessel walls and even tissue spaces, thereby promoting transmembrane gene transfection. The novel preparation provided by the invention is simple for preparation and convenient for usage, and does not require special production conditions.
Owner:钟志容
Recombinant lentivirus vector for treating beta-globulin afunction, preparation method and application
ActiveCN113046392AReduce usageImprove gene transfer efficiencyOrganic active ingredientsGenetic material ingredientsBeta thalassemiaSickle cell anemia
The application discloses a recombinant lentivirus vector for treating beta-globulin afunction, a preparation method and application. A gene element of the recombinant lentivirus vector disclosed by the application is composed of a left side lentivirus long terminal repeat, a lentivirus counter-response element, a center poly-purine sequence, a gene locus regulating and controlling sequence of a beta-globulin gene, a beta-globulin gene, of which 87-th threonine is mutated into glutamine, and a right side lentivirus long terminal repeat which are connected in order. According to the recombinant lentivirus vector disclosed by the application, through optimizing and improving the gene element, the gene transduction efficiency is increased, and the beta-globulin gene can be efficiently expressed during erythroid differentiation of hemopoietic stem cells, so that the consumption of viruses can be effectively lowered, and the treatment cost is reduced while the safety is improved. The recombinant lentivirus vector disclosed by the application provides a novel treatment tool and scheme for beta-thalassemia and sickle cell anemia caused by the beta-globulin afunction.
Owner:深圳市禾沐基因生物技术有限责任公司
Application of miR-31-5p in acute myelogenous leukemia
PendingCN113584166AGrowth inhibitionExtend your lifeOrganic active ingredientsMicrobiological testing/measurementCytarabineOncology
The invention relates to application of miR-31-5p in acute myelogenous leukemia, in particular to application of a product for detecting the miR-31-5p in preparation of a reagent, a chip or a kit for auxiliary diagnosis of subjects suffering from acute myelogenous leukemia (AML) and / or prognosis of the lifetime of the subjects. The invention also relates to an application of the miR-31 initial / precursor miRNA (prime / pre-miR-31) and / or the miR-31 mature miRNA (miR-31-5p) in preparation of a medicine for treating AML (acute myeloid leukemia). The miR-31-5p is introduced into cells through a gene transduction method, so bone marrow AML cells and leukemia stem cells (AML-LSC) can be induced to die, and the cytotoxicity of the chemotherapeutic drug cytarabine is enhanced; by expressing the miR-31-5p, the growth of AML cells and AML-LSC cells can be inhibited, and the life of animals can be prolonged. The disclosure provides a new method for diagnosis and prognosis evaluation of AML, and also provides a gene therapy drug for preparing AML.
Owner:JINAN UNIVERSITY
Method for improving low germination rate of sterile line of three lines of rice
InactiveCN102577929AEasy transduction processEfficient transduction processPlant genotype modificationAgricultural scienceGene
The invention relates to a method for improving the low germination rate of a sterile line of three lines of rice. The method is characterized in that Sanming dominant genic male sterile rice is taken as a carrier, the maintainer line of the low-germination-rate sterile line of three lines is taken as a recurrent parent, a Gm6 gene is transferred into the maintainer line of the low-germination-rate sterile line of three lines through 67 times of back-crossing, a fertile plant containing the homozygous Gm6 gene similar to the original maintainer line is obtained after self-crossing, a pedigree selection method is adopted in the generation-adding and homozygous process of the fertile plant to select a great quantity of individual plants for conducting continuous back-crossing, germination rate screening and parent difference removal by taking the original sterile line of three lines as a cytoplasm donor, and a new sterile line of three lines which is basically consistent with the original sterile line of three lines and satisfies the commercial standard on the germination rate can be obtained finally. The method has the advantages that the germination rate of the improved sterile line of three lines is improved and satisfies the commercial standard, the improved sterile line of three lines contains the Gm6 gene and the genetic constitutions of the improved sterile line of three lines are basically consistent with the genetic constitutions of the original sterile line of three lines.
Owner:福建省三明市农业科学研究所
Disulfide-stabilized anti-chloramphenicol single-chain antibody as well as construction method and application thereof
InactiveCN101935350AImprove stabilitySolve low-level expression problemsImmunoglobulinsBiological testingNatural antibodyDisulfide bonding
The invention discloses a disulfide-stabilized anti-chloramphenicol single-chain antibody as well as a construction method and application thereof. The amino-acid sequence of the anti-chloramphenicol single-chain antibody is shown as SEQ ID NO:1. The construction method comprises the following steps of: by using the variable region gene of the anti-chloramphenicol antibody as a template, respectively adding a cysteine site-directed mutation in the variable regions of a light chain and a heavy chain through primer mutation PCR (Polymerase Chain Reaction), assembling into a disulfide-stabilized anti-chloramphenicol single-chain antibody gene through overlap extension PCR, introducing synonymous mutation into the 5'-terminal 30bp sequence of the gene through the primer mutation PCR, and then transducing the gene into a colon bacillus expression system to obtain expressed protein, i.e. the disulfide-stabilized anti-chloramphenicol single-chain antibody. The construction form of a pair of disulfide bonds is introduced on the basis of the single-chain antibody into the anti-chloramphenicol single-chain antibody by simulating the structure of a natural antibody, and the stability of the antibody can be improved. The disulfide-stabilized anti-chloramphenicol single-chain antibody can replace a monoclonal antibody to be used for chloramphenicol residue detection.
Owner:GUANGDONG PHARMA UNIV
Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
ActiveUS8496941B2Efficiently reprogrammedEasy to removeSsRNA viruses negative-senseSugar derivativesReprogrammingHuman cell
Stem cell reprogramming genes cloned into a single sustained expression-type Sendai viral vector are shown to reprogram differentiated somatic cells into induced pluripotent stem (iPS) cells without integration of vector sequences into the host cell's genome. The genes are transduced into normal differentiated somatic cells via infection with recombinant Sendai virus. After expression of the reprogramming genes and subsequent induction of pluripotency, the vector genome RNA including the reprogramming genes is removed from the cell to establish an iPS cell that is genetically identical to the parent somatic differentiated cell thus reducing the risk of tumorigenic transformation caused by random integration of vector sequences into the host genome. The method promises to provide safe, autologous iPS cells that can be used for human cell replacement and regeneration therapeutic applications.
Owner:NAT INST OF ADVANCED IND SCI & TECH
Method for screening and constructing primary hepatocyte klotho gene transduction stem cells
The invention discloses a method for screening and constructing primary hepatocyte klotho gene transduction stem cells in the technical field of gene transduction stem cell screening and constructing methods. Drugs are screened by taking a T allelic site of rs648202 as a drug design target on the basis of a polymorphic DNA sequence of a klotho gene exon 4 region obtained by PCR (Polymerase Chain Reaction) amplification; and active molecules capable of adjusting the expression level of a klotho gene are screened out, polymorphic typing DNA fragment transduction is adopted based on human hepatocytes, and vector transduction is performed by sequentially adopting hTERT and pLXSN dual vectors, so that transduction of a pLXSN-hTERT expression vector for efficiently expressing hTERT is achieved, and the effect of constructing stem cells for efficiently expressing the klotho gene is achieved. In a low-solubility hygromycin double-screening culture system, the survival ability of the mesenchymal stem cells for tranducing the exogenous klotho gene is improved.
Owner:YANAN HOSPITAL OF KUNMING CITY
Solution of chitosan, preparation method thereof and using method thereof
ActiveCN101698712BAchieve dissolutionGenetic engineeringFermentationPOLYMER SUBSTANCEVector (molecular biology)
Owner:INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com